Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2024-07-24 | New | $2,900,000 | $2,900,000 | Equity and Debt | 06b | SEC link |
| 2023-10-03 | New | $5,000,004 | $5,000,004 | Equity Only | 06b | SEC link |
| 2022-11-15 | New | $20,000,000 | $20,000,000 | Equity Only | 06b | SEC link |
| 2019-03-27 | New | $1,250,000 | $1,250,000 | Equity and Debt | 06b | SEC link |
| 2014-10-23 | New | $9,000,000 | $9,000,000 | Equity Only | 06b | SEC link |
| 2014-08-22 | New | $4,742,648 | $4,742,648 | Equity Only | 06b | SEC link |
| 2014-02-14 | New | $3,225,000 | $3,225,000 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Thomas Adams | Director |
| Timothy Block | Director |
| John P. Brancaccio | Director |
| John Cavan | Executive |
| Bernard F. Denoyer | Director, Executive |
| Robert Foster | Director, Executive |
| Todd Hobbs | Executive |
| Bill Hornung | Executive |
| Gary S. Jacob | Director |
| Gary S. Jacobs | Director |
| Kaouthar Lbiati | Director |
| Arnold Lippa | Director |
| Christopher Mc Guigan | Director |
| Michael Purcell | Director |
| Anand Reddi | Director |
| James Sapirstein | Director, Executive |
| Petrus Wijngaard | Director |